Cost effectiveness of aspirin vs clopidogrel for secondary prevention of coronary heart disease
Lindbloom, E.J.; Eaton, L.J.
Journal of Family Practice 51(9): 789
2002
ISSN/ISBN: 0094-3509 PMID: 12366903 Document Number: 551408
Document emailed within 1 workday
Related Documents
Piamsomboon, C.; Laothavorn, P.; Chatlaong, B.; Saguanwong, S.; Nasawadi, C.; Tanprasert, P.; Leelaprute, M.; Intayakorn, U.; Amornsak, N. 2001: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up Journal of the Medical Association of Thailand 84(12): 1701-1707Martens, L.L.; Guibert, R. 1994: Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease Clinical Therapeutics 16(6): 1052-62; discussion 1036
Gaciong, Z. 2006: Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study Kardiologia Polska 64(5): 548
Hamilton, V.H.; Racicot, F.E.; Zowall, H.; Coupal, L.; Grover, S.A. 1995: The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C JAMA 273(13): 1032-1038
Wilhelmsen, L. 1982: Secondary prevention of coronary heart disease. A review Cor et Vasa 24(4): 216-227
Assmann, G. 1999: Secondary coronary heart disease prevention by red wine? Der Internist 40(9): 982
Pignone, M.; Mulrow, C. 2002: Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease Bmj 324(7342): 917
Jenni, D.; Osterwalder, R.; Osswald, S.; Buser, P.; Pfisterer, M. 2001: Are we treating coronary heart disease and heart failure appropriately in the clinic and ambulatory care? Secondary prevention and drug therapy 1998 Praxis 90(41): 1759-1765
Meinertz, T.; Heitzer, T. 2002: Primary and secondary prevention of coronary heart disease: smoking Zeitschrift für Kardiologie 91 Suppl. 2: 3-11
Wilhelmsen, L. 1977: Primary and secondary risk factors for coronary heart disease: their role in prevention Medical Journal of Malaysia 31(4): 296-301
Carneiro, Aónio.Vaz.; Costa, Jão.; Borges, M. 2004: Statins for primary and secondary prevention of coronary heart disease. A scientific review Revista Portuguesa de Cardiologia: Orgao Oficial da Sociedade Portuguesa de Cardiologia 23(1): 95-122
Klever-Deichert, G.; Hinzpeter, B.; Wendland, G.; Lauterbach, K. 2000: Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective Medizinische Klinik 95(6): 305-313
Wagner, M.; Goetghebeur, M.; Merikle, E.; Pandya, A.; Chu, P.; Taylor, D.C.A. 2009: Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada Canadian Journal of Clinical Pharmacology 16(2): E331-E345
Iushkenas, I.B.; Zhemaĭtite, D.I.; Stankus, A.I. 1987: The immediate effectiveness of rehabilitative treatment and secondary prevention in ischemic heart disease patients at Palanga health resort Kardiologiia 27(9): 50-54
Jost, S.; Lichtlen, P.R. 1995: Modifying increased plasma cholesterol levels in secondary prevention of coronary heart disease Zeitschrift für Kardiologie 84(8): 577-595
McKenna, C.J.; Sugrue, D.D. 1995: Secondary prevention in coronary heart disease. Fact: lowering cholesterol saves lives Irish Medical Journal 88(6): 191
Arnheim, K. 2000: Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids MMW Fortschritte der Medizin 142(24): 18
Enbergs, A.; Liese, A.; Heimbach, M.; Kerber, S.; Scheld, H.H.; Breithardt, G.; Kleine-Katthöfer, P.; Keil, U. 1997: Evaluation of secondary prevention of coronary heart disease. Results of the EUROSPIRE study in the Munster region Zeitschrift für Kardiologie 86(4): 284-291
Rupprecht, H.J. 2007: Coronary heart disease patient does not tolerate acetylsalicylic acid. can clopidogrel be prescribed? MMW Fortschritte der Medizin 149(14): 19
1980: Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group Circulation 62(3): 449-461